Translation of Data from Animal Models of Cancer to Immunotherapy of Breast Cancer and Chronic Lymphocytic Leukemia.

Reginald Gorczynski
Author Information
  1. Reginald Gorczynski: Institute of Medical Science, Department of Immunology and Surgery, University of Toronto, C/O 429 Drewry Avenue, Toronto, ON M2R 2K6, Canada. ORCID

Abstract

The field of clinical oncology has been revolutionized over the past decade with the introduction of many new immunotherapies the existence of which have depended to a large extent on experimentation with both in vitro analysis and the use of various animal models, including gene-modified mice. The discussion below will review my own laboratory's studies, along with those of others in the field, on cancer immunotherapy. Our own studies have predominantly dwelt on two models of malignancy, namely a solid tumor model (breast cancer) and lymphoma. The data from our own laboratory, and that of other scientists, highlights the novel information so obtained, and the evidence that application of such information has already had an impact on immunotherapy of human oncologic diseases.

Keywords

References

  1. Oncoimmunology. 2018 Feb 8;7(5):e1426517 [PMID: 29721394]
  2. PLoS One. 2017 Feb 24;12(2):e0171586 [PMID: 28234914]
  3. Cancer Res. 2010 Apr 1;70(7):2962-72 [PMID: 20332223]
  4. Cancer Med. 2016 Feb;5(2):325-36 [PMID: 26725371]
  5. Cancers (Basel). 2019 Jan 24;11(2): [PMID: 30682795]
  6. Blood. 2021 Dec 23;138(25):2621-2631 [PMID: 34940815]
  7. Dis Model Mech. 2019 Sep 6;12(9): [PMID: 31519693]
  8. Immunol Rev. 2017 Mar;276(1):52-65 [PMID: 28258699]
  9. Immunol Lett. 2016 Oct;178:105-13 [PMID: 27562325]
  10. Immunity. 1995 Nov;3(5):541-7 [PMID: 7584144]
  11. Hum Pathol. 2006 Feb;37(2):152-9 [PMID: 16426914]
  12. Curr Top Microbiol Immunol. 2005;294:135-45 [PMID: 16323430]
  13. Immunother Adv. 2023 Mar 30;3(1):ltad006 [PMID: 37082107]
  14. Blood. 2006 Dec 15;108(13):4194-7 [PMID: 16946299]
  15. Biochem Pharmacol. 2022 Apr;198:114970 [PMID: 35183530]
  16. Biomedicines. 2023 Dec 16;11(12): [PMID: 38137547]
  17. J Exp Med. 2009 Jul 6;206(7):1457-64 [PMID: 19564351]
  18. Neoplasia. 2016 Apr;18(4):229-41 [PMID: 27108386]
  19. Nat Cell Biol. 2014 Aug;16(8):717-27 [PMID: 25082194]
  20. PLoS One. 2014 Nov 19;9(11):e113597 [PMID: 25409195]
  21. Ann Diagn Pathol. 2020 Oct;48:151585 [PMID: 32829067]
  22. Cancer Lett. 2013 Aug 19;336(2):253-9 [PMID: 23523609]
  23. Leuk Res. 2018 May;68:40-47 [PMID: 29525600]
  24. Oncotarget. 2023 Feb 04;14:96-103 [PMID: 36738455]
  25. Breast Cancer Res Treat. 2012 Nov;136(1):117-27 [PMID: 23053647]
  26. Oncotarget. 2017 Mar 28;8(13):21609-21625 [PMID: 28423491]
  27. Immunity. 1997 Dec;7(6):885-95 [PMID: 9430233]
  28. Oncotarget. 2015 Dec 15;6(40):42825-37 [PMID: 26517517]
  29. Front Cell Dev Biol. 2021 Oct 08;9:739816 [PMID: 34692697]
  30. J Leukoc Biol. 2010 Aug;88(2):361-72 [PMID: 20442224]
  31. J Cancer. 2017 Feb 25;8(5):761-773 [PMID: 28382138]
  32. J Immunol. 2010 Dec 15;185(12):7216-22 [PMID: 21078907]
  33. Leuk Res. 2017 Jun;57:20-26 [PMID: 28273548]
  34. Heliyon. 2023 Aug 18;9(8):e19220 [PMID: 37654464]
  35. J Theor Biol. 2013 Jul 7;328:65-76 [PMID: 23541619]
  36. PLoS One. 2019 Jan 17;14(1):e0210796 [PMID: 30653571]
  37. J Clin Invest. 2007 Dec;117(12):3922-9 [PMID: 18008004]
  38. Cancer Res. 2014 Apr 1;74(7):1924-32 [PMID: 24691993]
  39. Transplantation. 2008 Oct 27;86(8):1116-24 [PMID: 18946351]
  40. Cancers (Basel). 2021 Mar 01;13(5): [PMID: 33804482]
  41. Blood. 2011 Nov 10;118(19):5201-10 [PMID: 21911837]
  42. BMC Cancer. 2009 Nov 11;9:394 [PMID: 19903360]
  43. J Exp Med. 2011 Feb 14;208(2):395-407 [PMID: 21300912]
  44. J Tissue Eng. 2014 Jul 17;5:2041731414544183 [PMID: 25383169]
  45. Cancer Immunol Immunother. 2020 Jul;69(7):1237-1252 [PMID: 32166404]
  46. J Transl Med. 2023 Jul 7;21(1):449 [PMID: 37420216]
  47. Int J Mol Sci. 2023 Oct 11;24(20): [PMID: 37894750]
  48. Oncotarget. 2017 Jul 21;8(36):60210-60222 [PMID: 28947965]
  49. J Clin Invest. 2017 Aug 1;127(8):3052-3064 [PMID: 28714866]
  50. J Cell Biochem. 2010 Feb 1;109(2):277-82 [PMID: 19950205]
  51. J Clin Invest. 2005 Jul;115(7):1797-805 [PMID: 15965501]
  52. Int J Oncol. 2009 Aug;35(2):297-308 [PMID: 19578743]
  53. Animal Model Exp Med. 2023 Oct;6(5):381-398 [PMID: 37679891]
  54. Nat Commun. 2017 Oct 13;8(1):924 [PMID: 29030636]
  55. Immunotherapy. 2016 Sep;8(9):1059-71 [PMID: 27485078]
  56. Front Oncol. 2021 Mar 10;11:645698 [PMID: 33777805]
  57. J Exp Med. 2003 Jul 7;198(1):63-9 [PMID: 12847137]
  58. Biosci Rep. 2020 Jul 31;40(7): [PMID: 32602545]
  59. Br J Haematol. 2003 Feb;120(3):452-6 [PMID: 12580959]
  60. Br J Haematol. 2009 Nov;147(4):471-83 [PMID: 19751240]
  61. Oncotarget. 2017 Mar 28;8(13):20741-20750 [PMID: 28186964]
  62. Eur Arch Otorhinolaryngol. 2013 Sep;270(10):2683-93 [PMID: 23632869]
  63. Cancer Res. 2010 Apr 15;70(8):3119-27 [PMID: 20354188]
  64. Cancer Cell. 2016 Dec 12;30(6):836-848 [PMID: 27960084]
  65. Leukemia. 2007 Mar;21(3):566-8 [PMID: 17252007]
  66. Breast Cancer. 2018 Sep;25(5):547-559 [PMID: 29532324]
  67. Oncogene. 2017 Aug 17;36(33):4692-4705 [PMID: 28394344]
  68. Am J Reprod Immunol. 2004 Aug;52(2):147-63 [PMID: 15274657]
  69. Oncoimmunology. 2020 Apr 7;9(1):1746554 [PMID: 32395395]
  70. J Immunother Cancer. 2020 Jun;8(1): [PMID: 32581043]
  71. Cancer Res. 2012 Oct 1;72(19):4931-43 [PMID: 22875025]
  72. Int J Mol Sci. 2023 Jul 21;24(14): [PMID: 37511495]
  73. Cancer. 2002 Sep 1;95(5):1071-5 [PMID: 12209693]
  74. J Oncol. 2019 Jan 21;2019:5689464 [PMID: 30800162]
  75. J Immunother Cancer. 2014 Dec 16;2(1):46 [PMID: 25598973]
  76. J Hematol Oncol. 2022 Mar 18;15(1):28 [PMID: 35303904]
  77. Neurosci Biobehav Rev. 2021 Oct;129:206-217 [PMID: 34352229]
  78. J Biomed Sci. 2022 Oct 17;29(1):83 [PMID: 36253762]
  79. Nat Cell Biol. 2008 May;10(5):593-601 [PMID: 18376396]
  80. iScience. 2023 May 19;26(6):106904 [PMID: 37275530]
  81. Nat Rev Cancer. 2012 Mar 22;12(4):252-64 [PMID: 22437870]
  82. Leuk Res. 2018 Mar;66:28-38 [PMID: 29353760]
  83. J Cell Biochem. 2007 Apr 1;100(5):1109-18 [PMID: 17131382]
  84. Blood. 2003 Nov 15;102(10):3837-44 [PMID: 12881305]
  85. Emerg Microbes Infect. 2013 Sep;2(9):e60 [PMID: 26038490]
  86. Adv Exp Med Biol. 2020;1223:155-165 [PMID: 32030689]
  87. Mol Cancer. 2017 Aug 29;16(1):148 [PMID: 28851377]
  88. Sci Rep. 2016 Dec 08;6:38689 [PMID: 27929051]
  89. Haematologica. 2020 Sep 28;106(10):2588-2597 [PMID: 33054128]
  90. Adv Immunol. 2006;90:297-339 [PMID: 16730267]
  91. Nature. 2002 Jan 31;415(6871):536-41 [PMID: 11823861]
  92. J Hematol Oncol. 2021 Sep 27;14(1):156 [PMID: 34579759]
  93. Neurotherapeutics. 2021 Jul;18(3):1980-1994 [PMID: 33829411]
  94. Adv Exp Med Biol. 2020;1240:47-58 [PMID: 32060887]
  95. Mol Cancer. 2022 Jan 21;21(1):28 [PMID: 35062949]
  96. Immunol Rev. 2017 Mar;276(1):97-111 [PMID: 28258697]
  97. Cancer Metastasis Rev. 2013 Jun;32(1-2):303-15 [PMID: 23114846]
  98. Mol Ther Oncolytics. 2021 Sep 14;23:138-150 [PMID: 34703882]
  99. Front Oncol. 2019 Mar 13;9:138 [PMID: 30918839]
  100. Oncogene. 2015 Jul;34(29):3860-70 [PMID: 25263452]
  101. Leuk Res. 2009 Mar;33(3):460-4 [PMID: 18838168]
  102. Clin Transl Med. 2023 Jun;13(6):e1303 [PMID: 37313656]
  103. Cancer Res. 2021 Oct 1;81(19):5021-5032 [PMID: 34183355]
  104. Cancer Immunol Immunother. 2020 Nov;69(11):2333-2343 [PMID: 32514618]

Grants

  1. unknown/CIHR

MeSH Term

Animals
Humans
Mice
Female
Breast Neoplasms
Leukemia, Lymphocytic, Chronic, B-Cell
Immunotherapy
Models, Animal

Word Cloud

Created with Highcharts 10.0.0cancerimmunotherapyfieldmodelsgene-modifiedmicestudiesbreastlymphomainformationCancerclinicaloncologyrevolutionizedpastdecadeintroductionmanynewimmunotherapiesexistencedependedlargeextentexperimentationvitroanalysisusevariousanimalincludingdiscussionwillreviewlaboratory'salongotherspredominantlydwelttwomalignancynamelysolidtumormodeldatalaboratoryscientistshighlightsnovelobtainedevidenceapplicationalreadyimpacthumanoncologicdiseasesTranslationDataAnimalModelsImmunotherapyBreastChronicLymphocyticLeukemiacytokines

Similar Articles

Cited By

No available data.